OSLO /LONDON ,May 28th 2021 :EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today provided an update regarding the ongoing phase I ACTIVATE study. Enrolment of patients in the study at theRoyal Marsden Hospital inLondon has been adversely impacted through the Covid-19 pandemic period. There have been seven patients enrolled in the study with five patients' data evaluable to date. A number of valuable and encouraging insights have been gained from this first cohort of treated patients, particularly with respect to application of ultrasound. In addition, as the organisation has expanded with appointment of experienced senior executives, focus has increased on improving quality management and internal governance processes. As a consequence, robust internal governance processes have been developed and implemented. In parallel, a protocol amendment is planned with a consequent impact on patient enrolment, which is anticipated to restart in Q4 2021. This additional foundational work will provide a strong platform to evaluate the exciting potential of Acoustic Cluster Therapy in oncology and other therapeutic segments. For more information contact: EXACT Therapeutics DrRafiq Hasan , CEO Rafiq@exact-tx.comOptimum Strategic Communications Mary Clark/Hollie Vile /Manel Mateus Tel: +44 (0) 203 922 1906 Email: Exact@optimumcomms.com About EXACT-Tx EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com About ACT® o ACT® comprises a proprietary formulation consisting of microbubbles and microdroplets that is activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology, however, the ACT® platform has potential across multiple therapeutic areas (infectious diseases, CNS, immunotherapy) and classes of therapeutic agents.
Click here for more information
© Oslo Bors ASA, source